Clinical Trial

Botulinum Toxin Type A for Frontal Hyperhidrosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Frontal hyperhidrosis is a form of primary focal hyperhidrosis that significantly impairs patients' quality of life due to excessive visible sweating in the forehead region. Conventional treatment options often show limited efficacy or may be associated with undesirable side effects. This study aims to evaluate the efficacy and safety of intradermal injections of Botulinum Toxin Type A in patients with primary frontal hyperhidrosis. Clinical outcomes will be assessed using Minor's iodine-starch test, the Hyperhidrosis Disease Severity Scale (HDSS), and patient satisfaction scores. Participants will be followed up one month after treatment to evaluate therapeutic response and potential adverse effects.
Protocol Amendment History 1 change
notable Sponsor changed: Tishreen University -> Latakia University 2026-07-19
Trial Details
NCT Number NCT07561580
Lead Sponsor Tishreen University
Conditions Primary Frontal Hyperhidrosis
Enrollment 30 participants
Start Date 2025-11-20
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-01